戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  assays, when the ADC (Trastuzumab-mcVC-PABC-Auristatin-0101) was incubated with plasma over a 144-h
2 in a majority of metastatic cancers, a CXCR4-auristatin ADC may be useful for the treatment of a vari
3                                         Dual-auristatin ADCs imparted activity in cell line and xenog
4  properties when compared to other synthetic auristatin analogues that are used in the preparation of
5      The design and synthesis of several new auristatin analogues with N-terminal modifications that
6 Conjugates of these multivalent ligands with auristatin and saporin toxins are efficiently internaliz
7   While two classes of potent anti-tubulins, auristatins and maytansinoids, indiscriminately radiosen
8 nes light onto the preferred binding mode of auristatins and serves as a valuable tool for structure-
9 tes of potent tubulin poisons (maytansinoids auristatins and taxoids) are undergoing clinical evaluat
10 ng a rationale for clinical translational of auristatin antibody drug conjugates with radio-immunothe
11              A chemically defined anti-CXCR4-auristatin antibody-drug conjugate (ADC) was synthesized
12 kers and payloads other than maytansines and auristatins, are more complex than those examined previo
13 he optimal ADC bears a non-cleavable linker, auristatin as payload at DAR = 4 and a low affinity anti
14 al growth phase, spheroids were treated with auristatin as small molecule (MMAE) or as antibody-drug
15                                    Using two auristatins as tool molecules, we demonstrate wide varie
16                                 In addition, auristatin cocrystal structures with tubulin are being p
17 fractory to ADCs comprised of the individual auristatin components.
18  and hydroxylamine functionalized monomethyl auristatin D with either protease-cleavable or noncleava
19 selectively and efficiently conjugated to an auristatin derivative through a stable oxime linkage.
20          We exemplify this using hydrophilic auristatin drug linkers and PEGylated ADCs that yield un
21 body-drug conjugate containing non-cleavable auristatin drug payload (033-F).
22 reparation of ADCs containing two classes of auristatin drug-linkers that have differing physiochemic
23 f the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), lin
24 DCs, the potent microtubule-disrupting agent auristatin E (AE) was incorporated through the norephedr
25 c drugs 5-fluorouracil (5-FU) and monomethyl auristatin E (MMAE) are partially activated by nontoxic
26  of the microtubule-destabilizing monomethyl auristatin E (MMAE) caged by a radiation-responsive phen
27 e microtubule destabilizing agent monomethyl auristatin E (MMAE) conjugated to the humanized anti-CD1
28  linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (MMAF), produces potent and hig
29 jugated with the cytotoxic agents monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF).
30                     The cytotoxic monomethyl auristatin E (MMAE) payload was introduced in the final
31 s with VC(S) linkers armed with a monomethyl auristatin E (MMAE) payload.
32 article-drug conjugates (NDCs) of monomethyl auristatin E (MMAE) significantly increase loading on a
33 es conjugated to radiosensitizing monomethyl auristatin E (MMAE) specifically produce CD8 T cell depe
34 ting to cAC10 the cytotoxic agent monomethyl auristatin E (MMAE) to create the antibody-drug conjugat
35 An ICAM1 antibody conjugated with monomethyl auristatin E (MMAE) via a protease-cleavable valine-citr
36 ed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific mono
37                  Here, model drug monomethyl auristatin E (MMAE) was conjugated ex vivo to Cys34 of a
38 sized that the anti-tubulin agent monomethyl auristatin E (MMAE), a component of a clinically approve
39 cally conjugated duocarmycin- and monomethyl auristatin E (MMAE)-based anti-PSMA ADCs with drug-to-an
40  promising target for antimitotic monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADC)
41                   Cytotoxicity of Monomethyl Auristatin E (MMAE)-EGFR-Pep11 peptide-drug conjugate wa
42 tion sites for the cytotoxic drug monomethyl auristatin E (MMAE).
43 and the antimicrotubule cytotoxin monomethyl auristatin E (MMAE).
44 er, and the microtubule inhibitor monomethyl auristatin E (MMAE).
45  F (mcMMAF) and valine-citrulline-monomethyl Auristatin E (vcMMAE) at interchain cysteine residues.
46 r antigen, linked to a cytotoxin (monomethyl auristatin E [MMAE]).
47 sosomal release functionality and monomethyl auristatin E as a cytotoxic payload.
48 ed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload.
49 ted release of the cytotoxic drug monomethyl auristatin E in combination with an antibody-drug conjug
50 lectin antibody valine-citrulline monomethyl-auristatin E in vivo, with more than 85% inhibition of t
51 of the ADC conjugated with either monomethyl auristatin E or F (vcMMAE/mcMMAF) displayed the same HDX
52 e was conjugated to the cytotoxin Monomethyl auristatin E via a cleavable linker to give the targeted
53 -binding fragments) conjugated to monomethyl auristatin E where the protein scaffold was labeled with
54 ic efficacy of the cytotoxic drug monomethyl auristatin E with the selectivity of the alpha(v)beta(6)
55                When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer ant
56 e (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expres
57 vered the same cytotoxic payload (monomethyl auristatin E, MMAE), and we found that the intracellular
58 ully human antibody conjugated to monomethyl auristatin E, targets a tumor-selective epitope of CD46,
59 al antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30(+) receptors.
60 lectin antibody valine-citrulline monomethyl-auristatin E, was a potent and selective agent against E
61 derivative of the cytotoxic tubulin modifier auristatin E, was covalently coupled to cAC10 through a
62                             However, a novel auristatin E-based antibody drug conjugate (ADC), E-sele
63 , a conjugate of OncoFAP with the monomethyl auristatin E-based Vedotin payload was well tolerated an
64          Brentuximab vedotin is a monomethyl auristatin E-conjugated monoclonal antibody directed aga
65 oxic microtubule-disrupting agent monomethyl auristatin E.
66 onjugated to the potent cytotoxin monomethyl auristatin E.
67  the microtubule-disrupting agent monomethyl auristatin E.
68 jugated via a cleavable linker to monomethyl auristatin E.
69 B (gpNMB) to the potent cytotoxin monomethyl auristatin E.
70 o a microtubule-disrupting agent, monomethyl auristatin E.
71  found to correlate with sensitivity to free auristatin E.
72 d to microtubule-disrupting agent monomethyl auristatin E.
73 d to the potent antimitotic agent monomethyl auristatin E.
74 A-targeted conjugate based on the monomethyl auristatin E.
75 geting Bicycle peptide, linked to monomethyl auristatin E.
76 bstrate with the caged cytotoxic (monomethyl auristatin E: MMAE; a high-affinity tubulin ligand).
77 nticancer drug N-phenyl maleimide monomethyl-auristatin-E (MMAE) maintained high cytotoxicity followi
78 tic agents such as paclitaxel and monomethyl-auristatin-E (MMAE).
79 led Lx, was coordinated to Desferal (DFO) or auristatin F (AF) to provide storable "semifinal" produc
80  conjugated with maleimidocaproyl-monomethyl Auristatin F (mcMMAF) and valine-citrulline-monomethyl A
81  via a single step with cytotoxic monomethyl auristatin F (MMAF) as payloads.
82 monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF).
83 arrying the structurally distinct monomethyl auristatin F were unaffected by SLC46A3 attenuation.
84 njugation to B-lactam-derivatized monomethyl auristatin F, the TrkB-targeting DVD-ADCs showed potency
85  the potent microtubule inhibitor monomethyl auristatin-F (MMAF) to lipid headgroups resulted in stri
86 to deliver the cytotoxic compound monomethyl-auristatin-F to HeLa cells is increased several fold in
87 of the microtubule-disrupting cytotoxic drug auristatin (FGFR2-ADC).
88  novel derivatives of the anti-tubulin agent auristatin, mediated potent antigen-dependent cytotoxici
89 the dominant mechanism of action in vivo was auristatin-mediated tumor cell killing.
90  An ADC conjugated via hinge-cysteines to an auristatin payload was used as a model in this study to
91 scribed, including the discovery of our lead auristatin, PF-06380101.
92 alanine phenylenediamine (AFP) or monomethyl auristatin phenylalanine (MMAF), two novel derivatives o
93 antibody-drug conjugates (ADC) consisting of auristatin phenylalanine phenylenediamine (AFP) or monom
94  therapeutic synergies of targeted cytotoxic auristatin radiosensitization to stimulate anti-tumor im
95                                              Auristatins, synthetic analogues of the antineoplastic n
96  immunoglobulin G (IgG) and conjugated to an auristatin through a stable, non-cleavable oxime linkage
97  the majority of the deconjugated mc-VC-PABC-auristatin ultimately is transferred to serum albumin, f
98 unotherapy paradigm using spatially targeted auristatin warheads.